MDC.L
Mediclinic International plc [MDC.L] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
MDC.L Stock Summary
In the News
MDC.L Financial details
Company Rating
Neutral
Market Cap
3.69B
Income
-320M
Revenue
3.08B
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
33.68K
Optionable
No
Shortable
Yes
Earnings
26 May 2023
P/E
24.46
Forward P/E
-
PEG
-0.42
P/S
1.14
P/B
1.19
P/C
-
P/FCF
9.85
Quick Ratio
0.66
Current Ratio
1.79
Debt / Equity
0.78
LT Debt / Equity
0.69
-
-
EPS (TTM)
-0.44
EPS next Y
-
EPS next Q
-
EPS this Y
128.26%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
2.41%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
2%
ROE
5%
ROC
0.04%
Gross Margin
16%
Oper. Margin
9%
Profit Margin
5%
Payout
-
Shs Outstand
737.24M
Shs Float
340.67M
-
-
-
-
Target Price
-
52W Range
0.0-514.0
52W High
-
52W Low
-
RSI
-
Rel Volume
-
Avg Volume
3.85M
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
0.421276
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-
MDC.L Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-03-31
| Metric | History | 2018-03-31 | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 3.89 | 3.98 | 4.18 | 4.06 | 4.39 | |
| Net income per share | -0.64 | -0.18 | -0.41 | 0.09 | 0.2 | |
| Operating cash flow per share | 0.47 | 0.47 | 0.62 | 0.32 | 0.75 | |
| Free cash flow per share | 0.28 | 0.26 | 0.48 | 0.32 | 0.51 | |
| Cash per share | 0.36 | 0.36 | 0.45 | 0.4 | 0.73 | |
| Book value per share | 4.46 | 4.27 | 3.92 | 3.86 | 4.21 | |
| Tangible book value per share | 2.67 | 2.28 | 2.49 | 2.59 | 2.88 | |
| Share holders equity per share | 4.46 | 4.27 | 3.92 | 3.86 | 4.21 | |
| Interest debt per share | 2.44 | 2.64 | 3.6 | 3.29 | 3.6 | |
| Market cap | 4.43B | 2.32B | 1.99B | 2.11B | 2.63B | |
| Enterprise value | 5.91B | 3.94B | 4.23B | 4.18B | 4.68B | |
| P/E ratio | -9.35 | -17.82 | -6.64 | 31.01 | 17.39 | |
| Price to sales ratio | 1.54 | 0.79 | 0.64 | 0.7 | 0.81 | |
| POCF ratio | 12.84 | 6.74 | 4.36 | 8.97 | 4.74 | |
| PFCF ratio | 21.82 | 12.19 | 5.61 | 8.97 | 7 | |
| P/B Ratio | 1.35 | 0.74 | 0.69 | 0.74 | 0.85 | |
| PTB ratio | 1.35 | 0.74 | 0.69 | 0.74 | 0.85 | |
| EV to sales | 2.06 | 1.34 | 1.37 | 1.4 | 1.45 | |
| Enterprise value over EBITDA | -18.75 | 12.2 | 12.74 | 11.7 | 9.09 | |
| EV to operating cash flow | 17.12 | 11.45 | 9.27 | 17.78 | 8.45 | |
| EV to free cash flow | 29.1 | 20.74 | 11.95 | 17.78 | 12.48 | |
| Earnings yield | -0.11 | -0.06 | -0.15 | 0.03 | 0.06 | |
| Free cash flow yield | 0.05 | 0.08 | 0.18 | 0.11 | 0.14 | |
| Debt to equity | 0.53 | 0.6 | 0.89 | 0.83 | 0.83 | |
| Debt to assets | 0.27 | 0.29 | 0.37 | 0.35 | 0.36 | |
| Net debt to EBITDA | -4.69 | 5.02 | 6.76 | 5.8 | 3.99 | |
| Current ratio | 1.83 | 1.86 | 1.58 | 1.8 | 1.79 | |
| Interest coverage | -4.75 | 2.82 | 1.44 | 2.22 | 4.52 | |
| Income quality | -0.72 | -2.51 | -1.66 | 2.26 | 2.63 | |
| Dividend Yield | 0.01 | 0.03 | 0.03 | 0 | 0 | |
| Payout ratio | -0.12 | -0.45 | -0.2 | 0 | 0 | |
| Sales general and administrative to revenue | 0.48 | 0.27 | 0.26 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.22 | 0.25 | 0.17 | 0.16 | 0.16 | |
| Capex to operating cash flow | -0.41 | -0.45 | -0.22 | 0 | -0.32 | |
| Capex to revenue | -0.05 | -0.05 | -0.03 | 0 | -0.06 | |
| Capex to depreciation | -0.85 | -0.92 | -0.47 | 0 | -0.79 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 8.03 | 4.12 | 5.98 | 2.83 | 4.41 | |
| ROIC | -0.06 | 0.03 | 0.02 | 0.02 | 0.03 | |
| Return on tangible assets | -0.1 | -0.03 | -0.05 | 0.01 | 0.02 | |
| Graham Net | -3.61 | -3.87 | -4.84 | -4.55 | -4.57 | |
| Working capital | 435M | 505M | 444M | 548M | 651M | |
| Tangible asset value | 1.97B | 1.68B | 1.83B | 1.91B | 2.12B | |
| Net current asset value | -2.01B | -2.07B | -2.74B | -2.47B | -2.49B | |
| Invested capital | 0.53 | 0.6 | 0.89 | 0.83 | 0.83 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 448M | 444M | 489.5M | 506.5M | 542M | |
| Average inventory | 90M | 89M | 96M | 106.5M | 103M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 87.29 | 92.7 | 95.91 | 70.76 | 78.41 | |
| Days of inventory on hand | 18.53 | 17.58 | 19.37 | 15.49 | 12.98 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 4.18 | 3.94 | 3.81 | 5.16 | 4.66 | |
| Inventory turnover | 19.7 | 20.76 | 18.85 | 23.57 | 28.12 | |
| ROE | -0.14 | -0.04 | -0.1 | 0.02 | 0.05 | |
| Capex per share | -0.19 | -0.21 | -0.14 | 0 | -0.24 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q2
| Metric | History | 2020-09-30 | 2021-03-31 | 2021-09-30 | 2022-03-31 | 2022-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.05 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.11 | 0 | 0 | 0 | 0 | |
| Operating cash flow per share | 0.15 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 0.15 | 0 | 0 | 0 | 0 | |
| Cash per share | 0.35 | 0 | 0 | 0 | 0 | |
| Book value per share | 3.94 | 0 | 0 | 0 | 0 | |
| Tangible book value per share | 2.55 | 0 | 0 | 0 | 0 | |
| Share holders equity per share | 3.94 | 0 | 0 | 0 | 0 | |
| Interest debt per share | 3.62 | 0 | 0 | 0 | 0 | |
| Market cap | 2.1B | 0 | 0 | 0 | 0 | |
| Enterprise value | 4.49B | 2.07B | 2.2B | 2.06B | 2.3B | |
| P/E ratio | -6.55 | 0 | 0 | 0 | 0 | |
| Price to sales ratio | 2.72 | 0 | 0 | 0 | 0 | |
| POCF ratio | 18.39 | 0 | 0 | 0 | 0 | |
| PFCF ratio | 18.39 | 0 | 0 | 0 | 0 | |
| P/B Ratio | 0.72 | 0 | 0 | 0 | 0 | |
| PTB ratio | 0.72 | 0 | 0 | 0 | 0 | |
| EV to sales | 5.82 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | 17.95K | 0 | 0 | 0 | 0 | |
| EV to operating cash flow | 39.37 | 0 | 0 | 0 | 0 | |
| EV to free cash flow | 39.37 | 0 | 0 | 0 | 0 | |
| Earnings yield | -0.04 | 0 | 0 | 0 | 0 | |
| Free cash flow yield | 0.05 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0.91 | 0.83 | 0.85 | 0.83 | 0.78 | |
| Debt to assets | 0.38 | 0.35 | 0.37 | 0.36 | 0.35 | |
| Net debt to EBITDA | 9.56K | 0 | 0 | 0 | 0 | |
| Current ratio | 1.58 | 1.8 | 1.88 | 1.79 | 1.49 | |
| Interest coverage | 4.05 | 0 | 0 | 0 | 0 | |
| Income quality | -1.43 | 0 | 0 | 0 | 0 | |
| Dividend Yield | 0.01 | 0 | 0 | 0 | 0 | |
| Payout ratio | -0.18 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.26 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.16 | 0.16 | 0.15 | 0.16 | 0.17 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 3.1 | 0 | 0 | 0 | 0 | |
| ROIC | 0.01 | 0 | 0 | 0 | 0 | |
| Return on tangible assets | -0.01 | 0 | 0 | 0 | 0 | |
| Graham Net | -4.81 | 0 | 0 | 0 | 0 | |
| Working capital | 444M | 548M | 639M | 651M | 508M | |
| Tangible asset value | 1.88B | 1.91B | 2.08B | 2.12B | 2.37B | |
| Net current asset value | -2.66B | -2.47B | -2.5B | -2.49B | -2.66B | |
| Invested capital | 0.91 | 0.83 | 0.85 | 0.83 | 0.78 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 84.86 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 22.96 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 1.06 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 3.92 | 0 | 0 | 0 | 0 | |
| ROE | -0.03 | 0 | 0 | 0 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
MDC.L Frequently Asked Questions
What is Mediclinic International plc stock symbol ?
Mediclinic International plc is a ZA stock and trading under the symbol MDC.L
What is Mediclinic International plc stock quote today ?
Mediclinic International plc stock price is $- today.
Is Mediclinic International plc stock public?
Yes, Mediclinic International plc is a publicly traded company.
Company Profile
- Volume Average 3.85M
- Market Capitalization 3.69B
- Employee 33.68K
- CEO Dr. Carel Aron van der Merwe D.A. (SA), F.C.A. (SA), M.B.Ch.B.
- Headquarters Stellenbosch,ZA
- IPO Date 2013-06-26
-
Website
https://www.mediclinic.com 
Mediclinic International plc, together with its subsidiaries, operates private hospitals. The company offers specialist-orientated and multidisciplinary healthcare services under the Mediclinic and Hirslanden brand names. It operates 74 hospitals, 20 day case clinics, 22 outpatient clinics, 5 subacute hospitals, 2 mental health facilities, and 453 theatres with approximately 11,538 inpatient beds in Switzerland, South Africa, Namibia, the Middle East, and the United Kingdom. The company also provides treasury, hospital equipment and procurement, emergency medical, management, food and catering, healthcare management, and debt collection and related services; manages healthcare staff; and owns and manages properties. In addition, it engages in the intellectual property holding and medical store/procurement businesses. The company was founded in 1983 and is based in Stellenbosch, South Africa.
